Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regenxbio (RGNX) Other Accumulated Expenses (2016 - 2025)

Historic Other Accumulated Expenses for Regenxbio (RGNX) over the last 12 years, with Q3 2025 value amounting to $929000.0.

  • Regenxbio's Other Accumulated Expenses rose 1804.32% to $929000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $929000.0, marking a year-over-year increase of 1804.32%. This contributed to the annual value of $649000.0 for FY2024, which is 4170.31% up from last year.
  • As of Q3 2025, Regenxbio's Other Accumulated Expenses stood at $929000.0, which was up 1804.32% from $736000.0 recorded in Q2 2025.
  • Over the past 5 years, Regenxbio's Other Accumulated Expenses peaked at $999000.0 during Q1 2023, and registered a low of $122000.0 during Q1 2021.
  • Moreover, its 5-year median value for Other Accumulated Expenses was $746000.0 (2022), whereas its average is $694368.4.
  • The largest annual percentage gain for Regenxbio's Other Accumulated Expenses in the last 5 years was 36344.09% (2021), contrasted with its biggest fall of 5864.41% (2021).
  • Over the past 5 years, Regenxbio's Other Accumulated Expenses (Quarter) stood at $744000.0 in 2021, then increased by 0.27% to $746000.0 in 2022, then tumbled by 38.61% to $458000.0 in 2023, then skyrocketed by 41.7% to $649000.0 in 2024, then skyrocketed by 43.14% to $929000.0 in 2025.
  • Its Other Accumulated Expenses was $929000.0 in Q3 2025, compared to $736000.0 in Q2 2025 and $779000.0 in Q1 2025.